4888.T JPX
Stella Pharma Corporation
1W: -0.5%
1M: +18.3%
3M: +37.0%
YTD: +23.8%
1Y: +5.7%
3Y: +32.3%
5Y: -25.9%
¥452.00 ($2.86)
+26.00 (+6.10%)
Weekly Expected Move ±6.2%
¥373
¥400
¥426
¥452
¥479
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$961M
+256.6% ▲
Gross Profit
$811M
+272.9% ▲
Operating Income
-$90M
+88.1% ▲
Net Income
-$141M
+81.6% ▲
EPS (Diluted)
$-4.22
+82.9% ▲
EBITDA
-$99M
+86.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $206M | $100M | $229M | $269M | $961M |
| YoY Growth | +0.0% | -51.4% | +128.8% | +17.6% | +256.6% |
| Cost of Revenue | $24M | $15M | $22M | $52M | $150M |
| Gross Profit | $182M | $85M | $207M | $217M | $811M |
| Gross Margin | 88.3% | 84.8% | 90.3% | 80.7% | 84.4% |
| R&D Expenses | $307M | $255M | $374M | $393M | $328M |
| SG&A Expenses | $539M | $555M | $625M | $571M | $901M |
| Operating Expenses | $862M | $827M | $1.0B | $978M | $901M |
| Operating Income | -$681M | -$742M | -$807M | -$760M | -$90M |
| Operating Margin | -330.4% | -741.2% | -352.2% | -282.1% | -9.4% |
| Interest Expense | $3M | $3M | $3M | $2M | $4M |
| Income Before Tax | -$656M | -$764M | -$776M | -$761M | -$138M |
| Tax Expense | $3M | $4M | $3M | $3M | $3M |
| Net Income | -$659M | -$768M | -$779M | -$764M | -$141M |
| Net Margin | -320.1% | -767.0% | -340.0% | -283.4% | -14.7% |
| EPS (Diluted) | $-32.90 | $-27.34 | $-26.97 | $-24.66 | $-4.22 |
| EBITDA | -$622M | -$727M | -$738M | -$724M | -$99M |
| Shares Outstanding | 28M | 28M | 29M | 31M | 33M |